Loading next page...
/lp/springer_journal/antiviral-prophylaxis-during-chemotherapy-or-immunosuppressive-drug-c9A0pTjvAo
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
- Subject
- Biomedicine; Pharmacology/Toxicology
- ISSN
- 0031-6970
- eISSN
- 1432-1041
- D.O.I.
- 10.1007/s00228-018-2487-4
- Publisher site
- See Article on Publisher Site
Abstract
Background Until recently, the role of antiviral prophylaxis in preventing hepatitis B virus (HBV) reactivation during immunosuppressive therapy or chemotherapy in patients with resolved HBV infection was unclear. The aim of the study reported here was to compare the efficacy of antiviral prophylaxis versus that of non-prophylaxis in resolved HBV-infected patients undergoing chemotherapy or immunosuppressive therapy. Methods PubMed, the Cochrane library, and the ClinicalTrials.gov website were searched from inception until December 2017. Studies comparing reactivation in prophylaxis versus non-prophylaxis in patients undergoing immu- nosuppressive therapy or chemotherapy were included. The meta-analysis was performed to calculate the relative risk (RR) and the pooled estimates. Results A meta-analysis was conducted of 13 studies (2 randomized controlled trials [RCTs] and 11 cohort studies). The summary RR for HBV reactivation was 0.47 (95% confidence interval [CI] 0.13–1.69) for antiviral prophylaxis versus non-prophylaxis. Both of the RCTs included in the meta-analysis enrolled patients treated with rituximab. Subgroup analyses showed that the two RCTs ± high-quality cohort studies showed a decreased risk of HBV reacti- vation among the antiviral prophylaxis groups (RCT 1: RR 0.13, 95% CI 0.02–0.70; P = 0.02; RCT 2: 0.28, 95% CI 0.08–0.98; P = 0.05). Subgroup analyses further showed that
Journal
European Journal of Clinical Pharmacology – Springer Journals
Published: May 29, 2018
@Phil_Robichaud
@deepthiw
@JoseServera